Latest Gout News

One-Third of Arthritis Patients Also Experience Anxiety, DepressionAllsup highlights importance of working closely with physicians for treatment and when applying for Social Security disability benefits Belleville, IL (PRWEB) May 24, 2012 A new national study finds that one-third of people with arthritis also experience anxiety or depression. This combination of physical and mental impairments points to the complexity of chronic illness and the importance of wor...

Pharma scrambling to expand gout treatment marketJoint pain caused by gout may be on its way out, as the ever-expanding market encourages the discovery of groundbreaking new therapies, according to a new report by healthcare experts GlobalData.

Women and their loved ones are affected by gout: SurveyAn online survey conducted by Red Hot Mamas North America, Inc. found that women and their loved ones are significantly affected by very painful bouts of gout, which they consider to be chronic and severe. Respondents indicated that although the debi...

May 22 is Gout Awareness Day: New gout recommendations highlight lifestyle changes as a key to managing acute gout symptomsPITTSBURGH, May 22, 2012 /PRNewswire/ -- New recommendations from the American Society of Clinical Rheumatologists (ASCR), published in Postgraduate Medicine[1], highlight updated management recommendations for patients with acute gout. These new recommendations come at a time when the incidence of gout is soaring; 8.3 million Americans are estimated to be gout patients[2]. To view the multi...

Study Finds Gout Significantly Impacts Lives of Women and Their Loved OnesBRIDGEWATER, N.J., May 22, 2012 /PRNewswire/ -- An online survey conducted by Red Hot Mamas North America, Inc. found that women and their loved ones are significantly affected by very painful bouts of gout, which they consider to be chronic and severe. Respondents indicated that although the debilitating pain associated with the condition affects quality of life, many individuals...

Rilonacept down but not out for gout flare preventionNEW YORK (Reuters Health) - On May 8, a panel of advisers to the U.S. Food and Drug Administration unanimously voted not to recommend approval of the interleukin-1 (IL-1) inhibitor rilonacept (Arcalyst, Regeneron Pharmaceuticals) for use in g...

Pharmos seeks gout bandwagon partner in last-chance saloonThe Iselin, New Jersey firm Pharmos is touting positive data from a proof-of-concept trial of its last remaining pipeline product in the hope of cashing in on the gout goldrush before its own purse is empty. The company has developed levotofisopam, a...

Pharmos' levotofisopam trial in gout earns positive resultsPharmos, a biopharmaceutical company based in Iselin, N.J., has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, goutPharmos Corporation today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of GoutISELIN, N.J., May 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a trial was conducted at the Duke Clinical Research Unit of Duke University and the principal investigator was John Sundy, M...

Ruga Corporation Acquires a Novel B-RAF Paradox Breaker Program from Selexagen Therapeutics, Inc.PALO ALTO, Calif., May 17, 2012 /PRNewswire/ -- Ruga Corporation, a privately held oncology company focused on the discovery and development of personalized therapeutics targeting tumor-selective adaptive responses, announced today that as part of its drug adaptation inhibitor program the company has acquired a novel RAF Kinase program to overcome the paradoxical activation of the MAPK pathwa...

D.C. Week: FDA Panels Endorse Two HIV DrugsWASHINGTON (MedPage Today) -- FDA advisory committees this week endorsed two new HIV drugs and an arthritis drug, and rejected an application for an investigational gout treatment.

Savient buys two years to fulfil 'impossible dream'Savient Pharmaceuticals, which is under pressure from its largest creditor to liquidate, has bought itself another two years to turn its disappointing gout therapy, Krystexxa (pegloticase) into a product that can sustain the company......

FDA panel doesn't support Regeneron drug for gout flaresRegeneron Pharmaceuticals' Arcalyst, or rilonacept, failed to gain endorsement from an FDA advisory panel for use in preventi -More-

Savient raises $44M, restructures debtSavient Pharmaceuticals Inc. (NASDAQ:SVNT) said on Wednesday it restructured debt and raised about $44 million through a sale of units comprising notes and warrants. The move comes after the Delaware Court of Chancery denied a request from creditor T...

Savient Pharmaceuticals Completes Financing and Debt Restructuring TransactionsEAST BRUNSWICK, N.J., May 9, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has completed the financing and debt restructuring transactions contemplated by certain Exchange and Purchase Agreements, dated May 7, 2012, between the Company and certain holders (the "Holders") of its currently outstanding 4.75% convertible senior notes due 2018 (the "Exis...

Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST (rilonacept) InjectionFDA Advisory Committee voted against approval of ARCALYST for the prevention of gout flares during initiation of uric acid-lowering therapy

US FDA Panel: Regeneron's Arcalyst not ready for goutWorried that doctors eager for new gout treatments would prescribe Regeneron's Arcalyst (rilonacept) for high-risk patients with aggressive or refractory disease, populations for which there is a lack of data, the US FDA's Arthritis Advisory.....

Regeneron: FDA Panel Says No to Arcalyst for GoutTARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. said Tuesday that a Food and Drug Administration panel has recommended its drug Arcalyst not be approved as a treatment for gout.

Savient's loss widens, shares fall(Reuters) - Savient Pharmaceuticals Inc posted a wider-than-expected loss on weak sales of its gout drug Krystexxa in the first two months, sending its shares down 13 percent.

UPDATE 2-Savient's loss widens, shares fallMay 9 (Reuters) - Savient Pharmaceuticals Inc posted a wider-than-expected loss on weak sales of its gout drug Krystexxa in the first two months, sending its shares down 13 percent.

USA: FDA panel votes against Regeneron gout drug; Court upholds Abilify patentThe US Food and Drug Administration's Arthritis Advisory Committee yesterday voted unanimously (11 to 0) against approval of US drugmaker Regeneron Pharmaceuticals' (Nasdaq: REGN) Arcalyst (rilonacept) injection for subcutaneous use for the proposed...

FDA advisors rule against Regeneron's Arcalyst for goutFDA advisors rule against Regeneron's Arcalyst for gout

Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) InjectionTARRYTOWN, N.Y., May 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against approval of ARCALYST® (rilonacept) Injection for Subcutaneous Use for the proposed indication for the prevention of gout flares in patients initiating uric acid-lowering the...

Savient Pharmaceuticals Reports First Quarter 2012 Financial ResultsEAST BRUNSWICK, N.J., May 9, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2012, which reflects the Company's continuing commercialization of KRYSTEXXA® (pegloticase) in the U.S. Savient ended the quarter with approximately $131.0 million in cash and short-term investments. On May 7, 2...

0 1 2 3 4 ›»

buy Gout market research data and corporate reports now Advertisement